Back to all studies
RecruitingNCT07184619

Evenamide 15 mg bid for schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States, in Argentina, in India, ... Confirm recruitment at each site. It is testing Evenamide 15 mg bid for schizophrenia.

SchizophreniaDrugOver 18 Years
In plain English

Key information made simple

What is this study testing?

This study is testing whether Evenamide 15 mg bid may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Evenamide 15 mg bid, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Argentina, in India, and in Malaysia.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: January 23, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
400
Sponsor
Newron Pharmaceuticals SPA
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Argentina, India, ...
Age range
Over 18 Years
Official registry ID
NCT07184619
Official title
A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)

Want help reviewing this study?

Loading the security check...
Study ID: NCT07184619. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Argentina · 1 site
  • Fundación para el Estudio y Tratamiento de las Enfermedades Mentales
    Buenos Aires, Buenos Aires F.D.
    Site status: Active Not Recruiting
India · 9 sites
  • Help Hospital
    Vijayawada, Andhra Pradesh
    Site status: Recruiting
  • Gauhati Medical College and Hospital
    Guwahati, Assam
    Site status: Recruiting
  • Masina Hospital Trust
    Mumbai, Maharashtra
    Site status: Recruiting
  • All India Institute Of Medical Sciences
    Nagpur, Maharashtra
    Site status: Not Yet Recruiting
  • New Manak Healthcare Hospital
    Navi Mumbai, Maharashtra
    Site status: Recruiting
  • Ahana Hospitals LLP
    Madurai, Tamil Nadu
    Site status: Recruiting
  • All India Institute of Medical Sciences
    Bībīnagar, Telangana
    Site status: Not Yet Recruiting
  • Udyan Health Care
    Lucknow, Uttar Pradesh
    Site status: Recruiting
  • Seth Sukhlal Karnani Memorial Hospital
    Kolkata, West Bengal
    Site status: Not Yet Recruiting
Malaysia · 4 sites
  • Kuala Lumpur Hospital
    Kuala Lumpur, Kuala Lumpur
    Site status: Recruiting
  • Hospital Tuanku Fauziah
    Kangar
    Site status: Recruiting
  • Sentosa Hospital
    Kuching
    Site status: Recruiting
  • Sultan Abdul Halim Hospital
    Sungai Petani
    Site status: Recruiting
United States · 5 sites
  • UCLA DGSOM, UCLA Health, UCLA Semel Institute
    Los Angeles, California
    Site status: Suspended
  • University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital
    Miami, Florida
    Site status: Suspended
  • Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine
    Atlanta, Georgia
    Site status: Suspended
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
    Baltimore, Maryland
    Site status: Suspended
  • Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research
    New York, New York
    Site status: Suspended
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Evenamide 15 mg bid, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Newron Pharmaceuticals SPA, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me